IDEAYA Biosciences Inc. has released its financial results for the first quarter of 2025. The company reported a net loss of $72.2 million for the three-month period ending March 31, 2025, which is a significant improvement compared to the net loss of $130.3 million for the previous quarter ending December 31, 2024. General and administrative expenses increased to $13.5 million from $11.0 million, primarily due to higher personnel-related, consulting, and legal patent expenses. The company reported cash, cash equivalents, and marketable securities of approximately $1.05 billion as of March 31, 2025, a slight decrease from approximately $1.08 billion at the end of December 2024. This reduction results from net cash used in operations, partially offset by $25.0 million in net proceeds from the sale of common stock shares through at-the-market financings during the quarter. In terms of business updates, IDEAYA is making progress with its darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial, having enrolled over 300 patients. The company is targeting median PFS results by the end of 2025 to potentially enable an accelerated approval filing. Additionally, IDEAYA has completed a successful FDA Type D meeting to finalize the darovasertib Ph3 registrational trial design and received U.S. FDA Breakthrough Therapy Designation in neoadjuvant UM. The company is also targeting three darovasertib program clinical data updates at medical conferences in 2025. Shanthakumar Tyavanagimatt, Ph.D., has joined IDEAYA as Senior Vice President, Technical Operations, to lead global commercial supply chain readiness and technical operations activities. IDEAYA has updated its cash runway guidance, projecting that its current cash balance will fund operations into 2029 based on its existing operating plan, with a focus on pipeline prioritization.